Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice

Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice

Show other versions (1)

The present study aims to assess the anxiolytic and hypnotic activity of ethanolic extract of Cocculus laurifolius leaf in mice. Anxiolytic activity was observed using behavioral paradigms while hypnotic activity was assessed by sodium pentobarbital induced hypnosis in mice. Animals were treated wit...

Full description

Bibliographic Details
Main Authors:	Sidra Maqbool, Ishrat Younus
Format:	Article
Language:	English
Published:	Bangladesh Pharmacological Society 2019-02-01
Series:	Bangladesh Journal of Pharmacology
Subjects:	Chemotherapy, Children, Chinese, Dinutuximab, Neuroblastoma, Regorafenib
Online Access:	https://www.bjp.asia/index.php/bjp/article/view/1

Similar Items

Anxiolytic and hypnotic effects of Cocculus laurifolius leaf extract in mice
by: Sidra Maqbool, et al.
Published: (2019-02-01)

Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma
by: Kun Dong, et al.
Published: (2019-02-01)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
by: Aleksandra Wieczorek, et al.
Published: (2023-02-01)

A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood
by: Michelle E. Keyel, et al.
Published: (2023-09-01)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
by: Margaret Cupit-Link, et al.
Published: (2023-09-01)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
by: Ruth Ladenstein, et al.
Published: (2020-01-01)

The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
by: Adeiye A. Pilgrim, et al.
Published: (2023-12-01)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
by: Tim Flaadt, et al.
Published: (2023-09-01)

Ex vivo expanded patient-derived γδ T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model
by: Jaquelyn T. Zoine, et al.
Published: (2019-08-01)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
by: Aleksandra Wieczorek, et al.
Published: (2022-04-01)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
by: Nur Olgun, et al.
Published: (2022-12-01)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
by: Holger N. Lode, et al.
Published: (2023-06-01)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
by: Filiz Cicek, et al.
Published: (2020-12-01)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
by: Claudia Paret, et al.
Published: (2022-12-01)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2023-06-01)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
by: Stefano Mastrangelo, et al.
Published: (2021-11-01)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
by: Kimberly J. Ornell, et al.
Published: (2020-04-01)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
by: Paula Martínez-Sanz, et al.
Published: (2021-08-01)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
by: Thomas Blom, et al.
Published: (2021-02-01)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
by: Aleksandra Wieczorek, et al.
Published: (2023-08-01)

Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials
by: Hunter C. Jonus, et al.
Published: (2022-12-01)

Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD<sub>2</sub> Antibody Dinutuximab Beta
by: Nikolai Siebert, et al.
Published: (2022-10-01)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
by: Sascha Troschke-Meurer, et al.
Published: (2023-01-01)

Monitoring Immune Responses in Neuroblastoma Patients during Therapy
by: Celina L. Szanto, et al.
Published: (2020-02-01)

Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study
by: Alessandro Ottaiano, et al.
Published: (2023-01-01)

Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles
by: Joshua R. Huot, et al.
Published: (2019-04-01)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
by: Donghao Xu, et al.
Published: (2022-03-01)

Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
by: Marina I. Sekacheva, et al.
Published: (2021-08-01)

Anxiolytic, sedative, and hypnotic activities of aqueous extract of Morinda citrifolia fruit
by: Sridharan Kannan, et al.
Published: (2014-01-01)

Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era
by: Augusto Leone, et al.
Published: (2022-08-01)

Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
by: Keigo Chida, et al.
Published: (2021-03-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience
by: Emmad E. Habib, et al.
Published: (2012-02-01)

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
by: Wang Qu, et al.
Published: (2024-01-01)

Osteosarcoma of rib treated with regorafenib: a case report
by: Cemre Uçaryılmaz, et al.
Published: (2021-03-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)